Thought you may be interested, broker CCZ Equities released its quarterly update report on CGS on 24th January. Makes for interesting and positive reading. In summary...
Forecasts and investment thesis strengthened.
Our financial forecasts and target price of $2.88 per share remains unchanged. The growing investment and the number of early stage Alzheimer's studies will strengthen CGS's short and long term sales pipeline, with FY23 backlog revenue as of Dec-21 already at $30.7m.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
0.050(2.79%) |
Mkt cap ! $312.3M | |||
| Open | High | Low | Value | Volume |
| $1.81 | $1.84 | $1.79 | $19.96K | 11.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.84 | 1424 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |